| Field | Specification |
|---|---|
| Target | |
| Alternative names | Phosphopantothenate--cysteine ligase; Phosphopantothenoylcysteine synthetase; PPC synthetase; PPCS; COAB |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human PPCS, which shares 73.9% and 78.2% amino acid (aa) sequence identity with mouse and rat PPCS, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects phosphopantothenate--cysteine ligase (gene PPCS) in human, mouse and rat samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 34.0 kDa, and the supplier reports an observed band at about 35 kDa.
Phosphopantothenoylcysteine synthetase (PPCS) catalyzes the second step of coenzyme A synthesis from vitamin B5, joining cysteine to 4′-phosphopantothenate. Because coenzyme A is required for fatty acid metabolism and energy production, PPCS is studied in CoA biosynthesis, and its mutations cause a form of dilated cardiomyopathy.
| Target | Phosphopantothenate--cysteine ligase (gene PPCS; UniProt Q9HAB8, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 34.0 kDa |
| Observed MW | 35 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
| IHC (frozen sections) | 0.5–1 µg/mL |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells |
Samples with a confirmed band (WB): human HeLa cells, human placenta tissue, human PC-3 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human intestinal cancer tissue, mouse small intestine tissue, rat small intestine tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with confirmed staining (ICC/IF): A549 cells, A431 cells.
Samples with a confirmed signal (flow cytometry): A431 cells.
Immunogen
Synthetic peptide from the C-terminal region of human PPCS. Sequence identity with the mouse and rat orthologs: 73.9% and 78.2%, respectively.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
